Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Neon’s initial Phase 1 clinical trial of NEO-PTC-01 will be conducted in patients with metastatic melanoma who are not responsive to checkpoint inhibitors.
Lead Product(s): NEO-PTC-01
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
Details:
This acquisition to expand BioNTech's capabilities and strengthens its immunotherapy pipeline.
Lead Product(s): NEO-STC-01
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $67.0 million Upfront Cash: $67.0 million
Deal Type: Acquisition January 16, 2020